To evaluate the health-related quality of life (HRQOL) for prostate cancer patients receiving androgen deprivation therapy (ADT).

We studied 200 patients with prostate cancer who were treated with primary ADT in Peking University People's Hospital from June 2014 to June 2015. The patients'average age was 73.9 years. The mean PSA level was 21.57 ng/ml when they were diagnosed with prostate cancer. Of these 200 patients, 79%(158/200) were localized and seclected ADT therapy due to age, body condition, basic diseases or individual will.21% (42/200) were locally advanced or metastasic, which accord with the indication of ADT therapy.The scales, including the MOS item short from health survey (SF-36), Functional Assessment of Cancer Therapy -General module (FACT-G), Functional Assessment of Cancer Therapy -Prostate instrument (FACT-P), Self-Rating Depression Scale (SDS) and Self-Rating Anxiety Scale (SAS) were used to evaluate their HRQOL.

According to results of SF-36, the physical health component score and mental health component score was 67.41±16.39 and 64.81±17.51, respectively. They indicated that the overall quality of life of these patients was at an acceptable level. And the average score of all domains exceeded 60 except general health domain, which the score was only 40.03±21.89. When it comes to FACT-P, the sum score, emotional well-being score and prostate cancer component score were 8.15±3.72, 12.30±4.04 and 77.41±9.95, respectively, which were less than half of their respective top score. However the physical well-being score was 20.41±4.29, which was a relatively satisfactory value. In addition, 61% (121/200) patient selected " not at all" in item " I am able to have and keep an erection" . The score of SDS and SAS was 46.76±8.29 and 43.25±9.69, respectively. And there were 23.0% (46/200) and 21.5% (43/200) patiens exhibited depression and anxiety, respectively.

In the present study, the prostate cancer patients receiving ADT showed acceptable HRQOL, but some patients sufferd from depression, anxiety and erectile dysfunction.

Prostate cancer; Androgen deprivation therapy (ADT); Health-related quality of life (HRQOL)